Amendment: SEC Form SCHEDULE 13D/A filed by Core Scientific Inc.

Item 3 of the Schedule 13D is hereby amended and restated as follows: The aggregate purchase price of the 2,263,789 shares of Common Stock directly held by the Strategic Fund reported herein was approximately $30,117,085. The aggregate purchase price of the 11,774,155 shares of Common Stock, 34,000 options to purchase Common Stock and 313,646 warrants directly held by the Global Fund reported herein was approximately $122,882,605. The aggregate purchase price of the 571,787 shares of Common Stock directly held by the Accounts reported herein was approximately $8,212,018. Further, the securities of the Issuer directly held by the Funds and Accounts were purchased with the working capital of the Funds and Accounts (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business).

Item 4 of this Schedule 13D is supplemented and superseded, as the case may be, as follows: On October 30, 2025, the Issuer announced that the Issuer's stockholders did not approve adoption of the Merger Agreement at the Special Meeting, and as a result the Issuer terminated the Merger Agreement effective immediately. TSC, a long-standing investor in the Issuer, continues to believe that the Issuer is a best-in-class asset and is enthusiastic about the Issuer's prospects as a standalone company.

Each of the Reporting Persons may be deemed to beneficially own 18,323,377 shares of Common Stock of the Issuer, which includes 313,646 shares of Common Stock issuable upon exercise of warrants and options to purchase 3,400,000 shares of Common Stock. Such amount of beneficial ownership represents approximately 5.9% of the shares of Common Stock outstanding, based on 310,061,300 shares of Common Stock outstanding as of October 20, 2025, based on information disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on October 24, 2025, plus 313,646 shares of Common Stock issuable upon the exercise of warrants held by the Funds. The Funds and Accounts have delegated to TSC sole voting and investment power over the securities held by the Funds and Accounts pursuant to their respective Investment Management Agreements with TSC. As a result, each of TSC, TSC GP, as the general partner of TSC, and Mr. Toussi, as Chief Investment Officer of TSC and Managing Member of TSC GP, may be deemed to exercise voting and investment power over the securities of the Issuer directly held by the Funds and Accounts. The Funds and Accounts specifically disclaim beneficial ownership of the securities of the Issuer directly held by them by virtue of their inability to vote or dispose of such securities as a result of their respective Investment Management Agreements with TSC. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference. The options to purchase Common Stock consist of options to purchase 3,400,000 shares of Common Stock held by the Global Fund with an exercise price of $15 per share that expire on January 16, 2026. The Global Fund sold options to purchase 1,300,000 shares of Common Stock with an exercise price of $20 per share that expire on November 21, 2025, and sold options to purchase 962,100 shares of Common Stock with an exercise price of $25 that expire on December 19, 2025. In addition, the Global Fund holds options to sell 962,100 shares of Common Stock with an exercise price of $20 per share that expire on December 19, 2025, and the Global Fund sold options to sell 962,100 shares of Common Stock with an exercise price of $15 per share that expire on December 19, 2025. The Strategic Fund sold options to purchase 187,200 shares of Common Stock with an exercise price of $25 that expire on December 19, 2025. In addition, the Strategic Fund holds options to sell 187,200 shares of Common Stock with an exercise price of $20 that expire on December 19, 2025, and the Strategic Fund sold options to sell 187,200 shares of Common Stock with an exercise price of $15 per share that expire on December 19, 2025. The Accounts sold options to purchase 50,700 shares of Common Stock with a purchase price of $25 that expire on December 19, 2025. In addition, the Accounts hold options to sell 50,700 shares of Common Stock with an exercise price of $20 per share that expire on December 19, 2025, and sold options to sell 50,700 shares of Common Stock with an exercise price of $25 that expire on December 19, 2025.

Items 7 through 10 of each of the cover pages of this Schedule 13D are incorporated herein by reference. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference.

Except as previously disclosed in this Schedule 13D, as amended, transactions by the Reporting Persons (on behalf of the Funds and Accounts) effected during the past 60 days are set forth in Exhibit 99.1 and such information is incorporated herein by reference.

The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated herein by reference. All securities reported in this Schedule 13D are directly held by the Funds and Accounts, each of which are investment management clients of TSC. The limited partners of (or investors in) each of the Funds and Accounts have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities of the Issuer held for the accounts of their respective Funds or Accounts in accordance with their respective limited partnership interests (or investment percentages) in their respective Funds or Accounts.

Not applicable.

Item 6 of this Schedule 13D is supplemented and superseded, as the case may be, as follows: Item 5 of this Schedule 13D is incorporated herein by reference.

Exhibit 99.1 Transactions Effected by the Reporting Persons (on Behalf of the Funds and Accounts) During the Past 60 Days.